Physician profile
Jared Simpson
NPI 1932368925
$8,984.18
in general payments reported to CMS, 2019-2025
27 companies · $1,106 in 2025
The $1,106 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,128 · 2022: $2,199 · 2023: $2,075 · 2024: $2,476 · 2025: $1,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,701 · Travel and Lodging: $938 · Education: $18.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,701.47 |
| Travel and Lodging | $937.53 |
| Education | $18.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,876.02 | 2021-2025 | General - Therapies, Watchman Access System, Watchman Flx |
| Abbott Laboratories | $922.89 | 2021-2025 | Ensite, Aveir, Quadra Allure Mp |
| E.R. Squibb & Sons, L.L.C. | $890.87 | 2021-2025 | Camzyos |
| Novartis Pharmaceuticals Corporation | $796.34 | 2021-2025 | |
| Pfizer INC. | $769.15 | 2021-2025 | |
| Amgen INC. | $686.97 | 2021-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $519.44 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $372.38 | 2021-2023 | Farxiga, Brilinta |
| Philips North America LLC | $359.76 | 2022-2024 | (Cm9) Amb Mon & Diag Und, (5044) Mcot |
| Janssen Pharmaceuticals, INC | $333.18 | 2021-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $258.87 | 2021-2025 | Verquvo, Capvaxive |
| Medtronic, INC. | $253.18 | 2024-2025 | Azure Xt Dr Mri Surescan, Micra |
| Impulse Dynamics (USA) INC. | $184.09 | 2025 | Optimizer |
| Actelion Pharmaceuticals US, INC. | $153.66 | 2022-2023 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals, LTD. | $113.79 | 2022-2023 | Arcalyst |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $98.64 | 2021-2025 | |
| Amarin Pharma, INC. | $79.12 | 2021-2022 | |
| Daiichi Sankyo INC. | $63.39 | 2023-2024 | Injectafer |
| Baxter Healthcare | $53.31 | 2023 | |
| Chiesi USA, INC. | $33.83 | 2021 | |
| Cvrx, INC. | $27.51 | 2025 | Barostim Neo System |
| Heartflow, INC. | $26.85 | 2025 | |
| Inspire Medical Systems, INC. | $26.85 | 2023 | Inspire |
| Atricure, INC. | $25.76 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.10 | 2025 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $19.64 | 2024 | |
| Recor Medical INC | $16.59 | 2024 | Paradise Renal Denervation System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.